MDAnderson Cancer Center Survivorship – Gynecologic Cancer: Bone Health

Making Cancer History*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



Copyright 2025 The University of Texas MD Anderson Cancer Center

Approved by the Executive Committee of the Medical Staff on 01/21/2025

Page 1 of 3

THE UNIVERSITY OF TEXAS MDAnderson Survivorship – Gynecologic Cancer: Bone Health Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's

Making Cancer History*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Adler, R. A. (2007). Cancer treatment-induced bone loss. Current Opinion in Endocrinology, Diabetes and Obesity, 14(6), 442-445. https://doi.org/10.1097/MED.0b013e3282f169b5
- Brown, J. E., Neville-Webbe, H., & Coleman, R. E. (2004). The role of bisphosphonates in breast and prostate cancers. *Endocrine-Related Cancer*, 11(2), 207-224. https://doi.org/10.1677/erc.0.0110207
- Brown, S. A., & Guise, T. A. (2009). Cancer treatment-related bone disease. *Critical Reviews in Eukaryotic Gene Expression*, 19(1), 47-60. https://doi.org/10.1615/CritRevEukarGeneExpr.v19.i1.20
- Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., . . . Watts, N. B. (2020). American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis 2020 update. *Endocrine Practice 26*(Suppl 1), 1-46. https://doi.org/10.4158/GL-2020-0524SUPPL
- Crandall, C., Petersen, L., Ganz, P. A., & Greendale, G. A. (2004). Bone mineral density and adjuvant therapy in breast cancer survivors. *Breast Cancer Research and Treatment, 88*(3), 257-261. https://doi.org/10.1007/s10549-004-0804-3
- Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019). Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism, 104*(5), 1595-1622. https://doi.org/10.1210/jc.2019-00221
- Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., . . . Van Poznak, C. H. (2013). NCCN task force report: Bone health in cancer care. *Journal of the National Comprehensive Cancer Network*, 11(Suppl 3), S-1 S-32. https://doi.org/10.6004/jnccn.2013.0215
- Hoff, A. O., & Gagel, R. F. (2005). Osteoporosis in breast and prostate cancer survivors. Oncology, 19(5), 651-658.
- Hu, M. I., Gagel, R. F., & Jimenez, C. (2007). Bone loss in patients with breast or prostate cancer. Current Osteoporosis Reports, 5(4), 170-178. https://doi.org/10.1007/s11914-007-0013-1
- LeBoff, M. S., Greenspan, S. L, Insogna, K. L, Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022). The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International, 33, 2049-2102. https://doi.org/10.1007/s00198-021-05900-y
- Limburg, C. E. (2007). Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer. *Oncology Nursing Forum*, 34(1), 55-63. https://doi.org/10.1188/07.ONF.55-36
- Reid, D. M., Doughty, J., Eastell, R., Heys, S. D., Howell, A., McCloskey, E. V., . . . Coleman, R. E. (2008). Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK expert group. *Cancer Treatment Reviews*, 34(1), S3-S18. https://doi.org/10.1016/j.ctrv.2008.03.007
- Tham, Y. L., Sexton, K., Weiss, H. L., Elledge, R. M., Friedman, L. C., & Kramer, R. M. (2006). The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. *Journal of Supportive Oncology*, *4*(6), 295-298.
- The North American Menopause Society. (2021). Management of osteoporosis in postmenopausal women: The 2021 position statement of the North American Menopause Society. *Menopause*, 28(9), 973-997. https://doi.org/10.1097/GME.00000000001831
- The University of Sheffield. (n.d.). Welcome to FRAX. Retrieved from https://www.sheffield.ac.uk/FRAX/
- U.S. Preventive Services Task Force. (2018). Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. *JAMA*, 319(24), 2521-2531. https://doi.org/10.1001/jama.2018.7498

Van Poznak, C., & Sauter, N. P. (2005). Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer, 104(3), 443-456. https://doi.org/10.1002/cncr.21201

Page 2 of 3

MDAnderson Cancer Center Survivorship – Gynecologic Cancer: Bone Health Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's

Making Cancer History*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Gynecologic Survivorship workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Huifang Lu, MD, PhD (Rheumatology) Jeena Varghese, MD (Endocrine Neoplasia & HD)

Workgroup Members

Therese Bevers, MD (Cancer Prevention) Wendy Garcia, BS[•] Katherine Gilmore, MPH (Cancer Survivorship) Thoa Kazantsev, MSN, RN, OCN[•] Ana Nelson, MSN, DNP, APRN, FNP-BC (Cancer Prevention) Johnny L. Rollins, MSN, APRN, ANP-C (Cancer Survivorship) Shannon Westin, MD (Gynecologic Oncology and Reproductive Medicine)

*Clinical Effectiveness Development Team

Page 3 of 3